For investors in Hong Kong

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE00B4R5TH58

NAV
HKD 16.46
As of 2023/06/02

1-Day Change
HKD 0.21 (1.29%)
 As of 2023/06/02

Morningstar Rating
As of 2023/04/30

Key investment risks:

  • The Fund's investments in equities are subject to equity market risk due to fluctuation of securities values.
  • Investments in the Fund involve general investment, currency, hedging, economic, political, policy, foreign exchange, liquidity, tax, legal, regulatory, securities financing transactions related and small/ mid-capitalisation companies related

More

  • risks. In extreme market conditions, you may lose your entire investment.
  • The Fund may invest in financial derivatives instruments for investment and efficient portfolio management purposes. This may involve counterparty, liquidity, leverage, volatility, valuation, over-the-counter transaction, credit, currency, index, settlement default and interest risks; and the Fund may suffer total or substantial losses.
  • The Fund's investments are concentrated in companies (may include small/ mid capitalization companies) with life sciences orientation and may be more volatile.
  • Investors should not only base on this document alone to make investment decisions and should read the offering documents including the risk factors for further details.

Less

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, PhD, CFA

Daniel Lyons, PhD, CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Discrete Performance (%)
As of 2023/03/31
A2 HKD
 
Quarter End
As of 2023/03/31 		Mar-2022 - Mar-2023 Mar-2021 - Mar-2022 Mar-2020 - Mar-2021 Mar-2019 - Mar-2020 Mar-2018 - Mar-2019
A2 HKD -0.38 3.17 39.50 -5.05 12.20
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.
Cumulative Performance (%)
As of 2023/04/30
A2 HKD
 
  Cumulative
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
2015/02/27
A2 HKD 3.90 1.85 6.99 2.67 11.02 31.53 58.85 65.20
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.
Calendar Year Returns (%)
As of 2023/03/31
A2 HKD
2022 2021 2020 2019 2018
A2 HKD -4.28 5.39 22.79 26.36 2.29
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.
FEE INFORMATION
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2021/12/31) 		2.37%
The ongoing charge is calculated using the Packaged Retail Investment Product (PRIIPs) methodology. The PRIIPs methodology differs to the UCITS ongoing charge methodology, as the PRIIPS methodology captures additional recurring charges, including but not limited to: a. Interest paid on borrowing (e.g. bank interest) b. Any fees incurred in relation to stock-lending activity (i.e. the fee paid to the lending agent) c. Any costs associated with holding closed-ended vehicles.
Please refer to the offering documents for more details on the fees and expenses.

Portfolio

Top Holdings (As of 2023/04/30)
% OF FUND
UnitedHealth Group Inc 6.20
AstraZeneca PLC 4.40
Eli Lilly & Co 3.17
Sanofi 2.98
Merck & Co Inc 2.94
Abbott Laboratories 2.80
AbbVie Inc 2.58
Novartis AG (ADR) 2.49
Thermo Fisher Scientific Inc 2.37
Boston Scientific Corp 2.29
Total 32.22
Portfolio holdings are subject to change without notice. 
Sector Allocation % OF FUND % OF FUND (As of 2023/04/30)
Regional Allocation % OF FUND % OF FUND (As of April 30, 2023)

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
What’s next for biotech’s M&A boom?
24 May 2023
Timely & Topical

What’s next for biotech’s M&A boom?

A regulatory hurdle may delay some merger and acquisition activity in the sector – but is unlikely to stop dealmaking.

4 min read

Biopharma delivers blockbuster growth
13 Apr 2023
Timely & Topical

Biopharma delivers blockbuster growth

How innovation is driving drug revenue growth in biopharma.

4 min read

Global Perspectives: Why biotech could be embarking on a new decade of growth
20 Mar 2023
Features & Outlooks

Global Perspectives: Why biotech could be embarking on a new decade of growth

A wave of innovative therapies is beginning to hit the market, transforming the prospects of the biotech firms behind the science.

24 min read